A variety of papers have observed the relationship between TGF-β2 expression and carcinomas in recent years, showing that increased TGF-β2 expression predicts a worse prognosis in breast cancer [10], gastric carcinoma [21], non-small-cell lung cancer [22], prostate cancer [23], and glioblastoma [24]. Here, TGFB2 is linked to Familial prostate cancer.